EU/3/19/2142: Orphan designation for the treatment of epidermolysis bullosa

losartan

Table of contents

Overview

On 26 February 2019, orphan designation (EU/3/19/2142) was granted by the European Commission to 3R Pharma Consulting GmbH, Germany, for losartan for the treatment of epidermolysis bullosa.

The sponsorship was transferred to Crowd Pharma Losartan GmbH & Co. KG, Germany, in March 2022.

Key facts

Active substance
losartan
Intended use
Treatment of epidermolysis bullosa
Orphan designation status
Positive
EU designation number
EU/3/19/2142
Date of designation
26/02/2019
Sponsor

Crowd Pharma Losartan GmbH & Co. KG
Merkurstrasse 8
Arlinger
Pforzheim
Baden-Wuerttemberg
75179
Germany
Email: losartan@crowdpharma.net

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating